{"id":716382,"date":"2022-12-02T16:58:01","date_gmt":"2022-12-02T21:58:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/"},"modified":"2022-12-02T16:58:01","modified_gmt":"2022-12-02T21:58:01","slug":"ibio-announces-ceo-departure","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/","title":{"rendered":"iBio Announces CEO Departure"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BRYAN, Texas, Dec.  02, 2022  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r7gq33Cp4rCqH-eX-KCzATUWf85reGbD6UCsVe1Ae2vnt-KcQKGyzltxJ2ZzVtbmAmQZWRebeMpjKteQ_9ehyQ==\" rel=\"nofollow noopener\" target=\"_blank\">iBio, Inc.<\/a> (NYSEA:IBIO) (\u201ciBio\u201d or the \u201cCompany\u201d), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors (the \u201cBoard\u201d) and Thomas F. Isett, the Company\u2019s Chief Executive Officer, have agreed that Mr. Isett will resign as a member of the Board and relinquish his duties, rights and obligations as an officer and CEO of the Company, effective immediately. While the Company continues its search for a successor, the leadership team will report to the current Chair of the Board, William (Chip) Clark.<\/p>\n<p align=\"justify\">\u201cTom has helped iBio\u2019s transformation into an AI-powered antibody discovery and development organization,\u201d said Mr. Clark. \u201cTom\u2019s leadership in the establishment of a portfolio of drug candidates, the acquisition of RubrYc\u2019s proprietary drug discovery engine, building the leadership team, and reshaping our Board of Directors has us positioned for our next chapter.\u201d<\/p>\n<p align=\"justify\">\u201cIt has been gratifying to have helped iBio through this dynamic and pivotal period of change,\u201d said Mr. Isett. \u201cI am confident the Company is in good hands. Many thanks and best wishes for everyone at iBio in the continuing journey to help bring new and better treatments to people suffering with cancer.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About iBio, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio\u2019s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oZ6MKkyGYD9qr8SHIWBrIfu18f4nLUI5rcYx3ItHLKIGjwaMG-FoTbpbtnT_v6X-p4dGP15DuTNhIjom-Zpy-g==\" rel=\"nofollow noopener\" target=\"_blank\">www.ibioinc.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Certain statements in this press release constitute \u201cforward-looking statements\u201d within the meaning of the federal securities laws. Words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201cpredict,\u201d \u201cforecast,\u201d \u201cproject,\u201d \u201cplan,\u201d \u201cintend\u201d or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding iBio continuing with a search for a new CEO. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, its ability to retain its key employees, or maintain its NYSE American listing; and the other factors discussed in the Company\u2019s filings with the SEC including the Company\u2019s Annual Report on Form 10-K for the year ended June 30, 2022 and the Company\u2019s subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>Stephen Kilmer<br \/>iBio, Inc.<br \/>(646) 274-3580<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=knZV3tCw3fqDJSYIVYns3n11hbi5IZ5uAelD9D102JB2rIHcB_v6v_6aqnnxuje1Ds97cYrJPdarNy7jAp6vu8-4PnPeSbe-9YgTRSOVvNo=\" rel=\"nofollow noopener\" target=\"_blank\">skilmer@ibioinc.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Relations<\/strong><br \/>\n        <br \/>Susan Thomas<br \/>IBio, Inc.<br \/>(619) 540-9195<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GqedmJ2n2fJRAKnwieNhCU5laxbLl3bAEpeMqnYwm55PtCh3RTLpGFWVFMIjdYJeqx7XdJ_KSlawiJGTuuMWmjT5zR1xbnHfzyBCH4DwFEk=\" rel=\"nofollow noopener\" target=\"_blank\">Susan.thomas@ibioinc.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwNzcxNCM1Mjk0NjE5IzIwODc1NzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OWE2ZDEyYjYtYWMyYy00OWE5LWE0N2YtNDM5YWZmYTIxZDVkLTEwOTkxNDQ=\/tiny\/iBio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NYSEA:IBIO) (\u201ciBio\u201d or the \u201cCompany\u201d), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors (the \u201cBoard\u201d) and Thomas F. Isett, the Company\u2019s Chief Executive Officer, have agreed that Mr. Isett will resign as a member of the Board and relinquish his duties, rights and obligations as an officer and CEO of the Company, effective immediately. While the Company continues its search for a successor, the leadership team will report to the current Chair of the Board, William (Chip) Clark. \u201cTom has helped iBio\u2019s transformation into an AI-powered antibody discovery and development organization,\u201d said Mr. Clark. \u201cTom\u2019s leadership in the establishment of a portfolio of drug candidates, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;iBio Announces CEO Departure&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-716382","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>iBio Announces CEO Departure - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iBio Announces CEO Departure - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NYSEA:IBIO) (\u201ciBio\u201d or the \u201cCompany\u201d), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors (the \u201cBoard\u201d) and Thomas F. Isett, the Company\u2019s Chief Executive Officer, have agreed that Mr. Isett will resign as a member of the Board and relinquish his duties, rights and obligations as an officer and CEO of the Company, effective immediately. While the Company continues its search for a successor, the leadership team will report to the current Chair of the Board, William (Chip) Clark. \u201cTom has helped iBio\u2019s transformation into an AI-powered antibody discovery and development organization,\u201d said Mr. Clark. \u201cTom\u2019s leadership in the establishment of a portfolio of drug candidates, &hellip; Continue reading &quot;iBio Announces CEO Departure&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-02T21:58:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwNzcxNCM1Mjk0NjE5IzIwODc1NzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"iBio Announces CEO Departure\",\"datePublished\":\"2022-12-02T21:58:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/\"},\"wordCount\":546,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwNzcxNCM1Mjk0NjE5IzIwODc1NzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/\",\"name\":\"iBio Announces CEO Departure - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwNzcxNCM1Mjk0NjE5IzIwODc1NzM=\",\"datePublished\":\"2022-12-02T21:58:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwNzcxNCM1Mjk0NjE5IzIwODc1NzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODcwNzcxNCM1Mjk0NjE5IzIwODc1NzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ceo-departure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iBio Announces CEO Departure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iBio Announces CEO Departure - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/","og_locale":"en_US","og_type":"article","og_title":"iBio Announces CEO Departure - Market Newsdesk","og_description":"BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NYSEA:IBIO) (\u201ciBio\u201d or the \u201cCompany\u201d), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors (the \u201cBoard\u201d) and Thomas F. Isett, the Company\u2019s Chief Executive Officer, have agreed that Mr. Isett will resign as a member of the Board and relinquish his duties, rights and obligations as an officer and CEO of the Company, effective immediately. While the Company continues its search for a successor, the leadership team will report to the current Chair of the Board, William (Chip) Clark. \u201cTom has helped iBio\u2019s transformation into an AI-powered antibody discovery and development organization,\u201d said Mr. Clark. \u201cTom\u2019s leadership in the establishment of a portfolio of drug candidates, &hellip; Continue reading \"iBio Announces CEO Departure\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/","og_site_name":"Market Newsdesk","article_published_time":"2022-12-02T21:58:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwNzcxNCM1Mjk0NjE5IzIwODc1NzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"iBio Announces CEO Departure","datePublished":"2022-12-02T21:58:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/"},"wordCount":546,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwNzcxNCM1Mjk0NjE5IzIwODc1NzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/","name":"iBio Announces CEO Departure - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwNzcxNCM1Mjk0NjE5IzIwODc1NzM=","datePublished":"2022-12-02T21:58:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwNzcxNCM1Mjk0NjE5IzIwODc1NzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODcwNzcxNCM1Mjk0NjE5IzIwODc1NzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ceo-departure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"iBio Announces CEO Departure"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/716382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=716382"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/716382\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=716382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=716382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=716382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}